FDA approval of RASONQUE is the key catalyst — this is Revolution Medicines' first commercial product. The $250M non-dilutive debt draw funds launch infrastructure without equity dilution. Monitor first commercial launch metrics in the next quarterly filing for RASONQUE revenue trajectory and whether the remaining $500M loan tranches are subsequently drawn.
Price Chart
Executive Summary
Revolution Medicines triggered a $250M Tranche A loan draw from Royalty Pharma upon FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma. The company also elected not to take the $250M Tranche 3 royalty sale option, forgoing that capital. The $250M debt facility provides non-dilutive funding to support commercialization, while the declined royalty sale preserves future revenue streams but leaves $500M in potential future financing untapped.
Key Facts
- FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma on or around October 8, 2026
- Revolution Medicines drew $250M Tranche A loan from Royalty Pharma at SOFR + 5.75% (3.50% floor), interest-only, due October 8, 2032
- Company paid a $5M draw fee on the Tranche A loan
- Company elected not to take the $250M Tranche 3 royalty sale option, preserving 100% of RASONQUE revenue
- Up to $500M in additional loans and $500M in additional royalty purchase payments remain available upon meeting milestones
Financial Impact
$250M debt drawn at SOFR + 5.75% (interest-only through 2032); $5M draw fee paid; $250M royalty sale declined (revenue preserved)
Risk Factors
- RASONQUE faces commercial execution risk in a competitive pancreatic cancer market
- Floating-rate debt (SOFR + 5.75%) exposes the company to rising interest costs
- Remaining $500M in potential future financing is contingent on milestones that may not be achieved
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628171-26-000004 |
| Document: 0001628171-26-000004-index.html | 0001628171-26-000004 |
| Document: 0001628171-26-000004.txt | 0001628171-26-000004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | Institutional Cluster | $187.53 | awaiting T+60 | — | $183.68 (−2.05%) |
Oct 21, 2026 4d ago | Press Release | $187.69 | awaiting T+60 | — | $183.68 (−2.14%) |
Oct 13, 2026 12d ago | 8-K | $193.52 | awaiting T+60 | — | $183.68 (−5.08%) |
Oct 12, 2026 14d ago | Institutional Cluster | $193.95 | awaiting T+60 | — | $183.68 (−5.30%) |
Oct 1, 2026 24d ago | Insider Cluster | $206.64 | awaiting T+60 | — | $183.68 (−11.11%) |
Sep 29, 2026 26d ago | Insider Cluster | $205.26 | awaiting T+60 | — | $183.68 (−10.51%) |
Sep 28, 2026 27d ago | Insider Cluster | $204.48 | awaiting T+60 | — | $183.68 (−10.17%) |
Sep 24, 2026 4w ago | Insider Cluster | $204.97 | awaiting T+60 | — | $183.68 (+10.39%) |
Sep 22, 2026 4w ago | Insider Cluster | $190.74 | awaiting T+60 | — | $183.68 (+3.70%) |
Sep 18, 2026 5w ago | Insider Cluster | $192.76 | awaiting T+60 | — | $183.68 (+4.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers